JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 195 patients (estimated)
- Sponsors
- Janssen Research & Development LLC
- Tags
- B-Cell Maturation Antigen (BCMA), CD3, GPRC5D, Tri-specific Antibody
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1883
- NCT Identifier
- NCT05652335
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.